// App-Quantinova.ai

642 : EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 EOGBM1–18/ROSALIE study

Researchers

Presenter

  • David Reardon

Principal Investigators

  • Maria Vieito

  • Ghazaleh Tabatabai

  • Agostina Stradella

  • Francois Ghiringhelli

  • Michael Burger

  • Iris Mildenberger

  • Ulrich Herrlinger

  • Macarena Gonzalez

  • Marta GilMartin

  • Mirjam Renovanz

  • Mehdi Touat

  • Patrick Wen

  • Antje Wick

  • Cecile Gouttefangeas

  • Ana Maia

  • Chistophe Bonny

  • Jan Fagerberg

  • Wolfgang Wick

Medical Centers

  • University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany

  • universitätsklinikum tübingen, Tübingen, Germany

  • Medizinische Fakultät, Mannheim, Germany

  • Dana-Farber Cancer Institute, Boston, MA

  • Hospital Universitari Vall -Hebron. Ciberehd., Barcelona, Spain

  • Universitatsklinkum Frankfurt am Main Goethe Universitat, Frankfurt, Germany

  • Hopital Universitaire Pitie-Salpetriere, Paris, France

  • Institut Catala d Oncologia, Hospital Duran i Reynals, Barcelona, Spain

  • Center Georges-Francois Leclerc, Dijon, France

  • Department of Neurosurgery, Eberhard Karls University, Tubingen, Germany

  • Enterome, Paris, France

Locations

  • Germany

  • France

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

  • Bevacizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT04116658

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved